Salisbury Foundation Trust


Internal Reference Number: FOI_6033

Date Request Received: 10/02/2021 14:58:21

Date Request Replied To: 12/02/2021 13:12:58

This response was sent via: By Email

Request Summary: treatment of Lung Cancer

Request Category: Researcher

Question Number 1:
Could you please provide the total number of patients with any treatment in the last three months for:
• Total non-small cell lung cancer (NSCLC)
• BRAF+ non-small cell lung cancer (NSCLC)
Answer To Question 1:
Please see attached refusal notice, explaining why the Trust will not be answering this FOI. Thank you.
Question Number 2:
In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:
• Afatinib
• Alectinib
• Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
• Atezolizumab monotherapy
• Bevacizumab
• Brigatinib
• Ceritinib
• Crizotinib
• Dacomitinib
• Dabrafenib with Trametinib
• Docetaxel monotherapy
• Durvalumab
• Erlotinib
• Gefitinib
• Gemcitabine
• Nintedanib with Docetaxel
• Nivolumab
• Osimertinib
• Paclitaxel
• Pembrolizumab chemo in combination
• Pembrolizumab monotherapy
• Pemetrexed with Carboplatin
• Pemetrexed with Cisplatin
• Vinorelbine and cisplatin/carboplatin
Answer To Question 2:
Please see answer to question 1.
To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Salisbury NHS Foundation Trust, Salisbury District Hospital, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E:
© 2022 Salisbury NHS Foundation Trust
Trust Values